LLY241206P685000
- 0.10
- -0.10-50.00%
Eli Lilly and Co Newsroom
Jefferies Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $994
Eli Lilly & Co (LLY) Gets a Buy From Jefferies
Why Is Eli Lilly and Company (LLY) Among Louis Navellier's Top Stock Picks Heading Into 2025?
Eli Lilly and Novo Nordisk's Obesity Moat Just Got Stronger -- Heard on the Street -- WSJ
S&P 500 Posts Weekly Rise to Fresh Record, Ends November With Strongest Monthly Gain of Year
10 Health Care Stocks With Whale Alerts In Today's Session
Behind the Scenes of Eli Lilly's Latest Options Trends
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Viking Therapeutics Stock On Brink Of Death Cross As Weight Loss Hype Loses Momentum
Wednesday Ends With Index Decline | Wall Street Today
Short Stock Ideas From Each Sector With Earnings Quality in the Bottom 20%
Dow Hits Another Record, Core PCE 2.8% as Expected | Live Stock
Eli Lilly's Flortaucipir Approved by UK Regulator to Test for Alzheimer's Disease
LLY, NVO Stock Up as Biden Proposes Medicare Cover for Obesity Drugs
Express News | Mhra: Approves Flortaucipir (Tauvid) for Adults Showing Signs of Cognitive Impairment for Alzheimer’s Disease
Erste Group Downgrades Eli Lilly and Co(LLY.US) to Hold Rating
Trump Taps Jay Bhattacharya to Lead National Institutes of Health
Wells Fargo Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,000
Will weight loss drugs be included in the US medical insurance, becoming the strongest "roadblock" for the Trump team?
The "Dual Weight Loss Champions" led the significant rise.
Top Gap Ups and Downs on Tuesday: LLY, ZM, BBY and More